Assertion: active ankylosing spondylitis | /r/CapableOf | respond to tnfαblockers
Facets:
value: inadequately
type: MANNER
Source sentences:
text: Interleukin-17A inhibitor secukinumab is an option for the treatment of active ankylosing spondylitis that has responded inadequately to (TNFα) blockers.